

Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold)

For Professional and Self-test Use in Saliva





COVID-19 Antigen

Patients with COVID-19 infection often show the SARS-CoV-2 nucleocapsid protein antigen positive. It is detectable in saliva swab specimen during the acute phase of infection Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.



Intended use

This product is intended for the qualitative detection of COVID-19 antigen iin saliva swab from suspected individuals of symptomatic or asymptomatic with COVID-19 infection within the first seven days of symptom onset.



SARS-CoV-2 has several structural proteins including spike (S), envelope (E), membrane (M) and nucleocapsid (N). This Test Kit is a lateral flow chromatographic immunoassay intended for the



Product information

Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold)

Short Rapid detection of novel coronavirus detection time No need for instruments and equipment, instru mentation suitable for rapid screening required **Test principle** Possess high consistency in the detection of Detectable delta and the other variants with the original type for variants qualitative detection of the N protein antigen.

Product characteristics

sample

25 tests / box,1 test / unit

Saliva

4 C-30 C

Product name	Specifications	Storage Conditions

Changzhou Biowin Pharmaceutical Co., Ltd.

EC REP CERTIFICATE



CMC MEDICAL DEVICES & DRUGS SL NO. CMC/CE/2021/07092021.6

CONFIRMED THAT CMC MEDICAL DEVICES & DRUGS S.L. Is the European Authorized Representative of

Changzhou Biowin Pharmaceutical Co., Ltd.
Building 3,Caltech port,218 Fumin Road,
Changzhou Economic Development Zone, Changzhou, China

The certificate remains valid until the expiration agreement of EC REP, manufacturing conditions, the quality system or relevant legislation are changed. The validity is conditioned by positive results of periodic surveillance audits.

The product liability rests with the manufacturer in accordance with applicable directive and standard, after fulfilling of the relevant EU legislation requirements, the manufacturer shall affix relevant CE marking to all above mentioned models of the medical device.

Complies with the applicable essential requirements of the council directive 98/79/EEC on in vitro diagnostics as amended.

From 26 May 2022, manufacturer must fully comply with the IVDR in order to be placed their products in the European market.

The products in Annex I was registered in Spanish MOH with number RPS/1999/2021

CE

Issued on: 07/09/2021

Valid until: 29/03/2022

CMC Medical Devices & Drugs SL

www.cmcmedicaldevices.com

EC REP CERTIFICATE



ANNEX I Medical Device Product

Myoglobin Diagnostic Test Kit (Colloidal Gold)

TroponinI Diagnostic Test Kit(Colloidal Gold)

Disposable Fecal Test Sampler

Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) (For Saliva)

Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold)(For Nasal)



www.cmcmedicaldevices.com

CE EC Declaration of Conformity

Manufacturer:

Changzhou Biowin Pharmaceutical Co.,Ltd.

Add: Building3, Caltech port, 218 Fumin Road, Changzhou

Economic Development Zone, Changzhou, China

Whose Single

CMC Medical Devices & Drugs S.L.

Authorized EU-

Add: C/Horacio Lengo Nº 18, CP 29006, Málaga-Spain

Representative:

Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal

Product Name:

Gold) (For Saliva)

Classification: Others of ANNEX II of IVDD

Conformity Assessment Route: Annex III

We herewith declare that the above mentioned products meet the transposition into national law, the provisions of the following EC Council Directives and Standards. All supporting documentations are retained under the premises of the manufacturer.

General applicable directives:

In Vitro Diagnostic Medical Devices DIRECTIVE 98/79/EC

Harmonized standards:

EN ISO 13485:2016,EN ISO 15223-1:2016,EN ISO 14971:2012, EN 13641: 2002, EN ISO 18113-1:2011, EN ISO 18113-2:2011, EN ISO 23640:2015

Signature:

Name:

Title:

Place/Date:

General manager

China Sept 3, 2021



Suzhou LQA Standard Certification Co., Ltd.

QUALITY MANAGEMENT SYSTEM CERTIFICATE

This certifies that the Quality Management System of

Changzhou Biowin Biopharm Co., Ltd.

Unified Social Credit Code: 913204055866144395

3rd Floor, Building 3, California Technology Port, No.218, Fumin Road,

Changzhou City, Jiangsu Province, P. R. China 213000

Medical devices Quality Management Systems Requirements for Regulatory Purposes:

YY/T 0287-2017/ISO 13485:2016

Scope of Certification:

Design, Production and Service of In Vitro Diagnostic Reagents (Within the Scope of Registration)

Certificate Number:

33220M40006R0S

Certificate Issue Date:

10-Jun-2020

Initial Registration Date:

10-Jun-2020

First Surveillance Second Surveillance

Expiration Date:

09-Jun-2023

Audit Audit

This certificate is valid within the period of the administrative license and qualification prescribed by state;

The certified organization must do the regular surveillance audit, get valid audit conclusion and add the surveillance identification to maintain the effective of the certificate.

Address: No.209 Zhuyuan Rd. Suzhou City, Jiangsu Province, China(215011)

The Certificate information can be searched on the website of CNCA (www.cnca.gov.cn)

44×44×58

XBioWin 新型冠状病毒(COVID-19)抗原 核調试剂盒(胶体金法) Novel Coronavirus (COVID-19) AntigenTest Kit (Colloidal Gold) 常州博闻迪医药股份有限公司 Changthou Brown Pharmaceutical Co. Ltd	A REPORT AND	X BioWin 新型冠状病毒(COVID-19)抗原 检測试剂盒(胶体金法) Novel Coronavirus(COVID-19) AntigenTest Kit(Colloidal Gold) 第州博闻迪医药設份有限公司 Changthon Mowin Pharmacoutical Co. Ltd 公司均址元第年時前超升在重視214号3月時日間号度 Activity (1984年) 中国 (1984年) 日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本	SET OF STATE OF STAT

length * width * height	13.5*6.5cm 14*14*14cm
length * width * height	14*14*14cm
Sboxes per box	900Tests
ngth * width * height	44*44*58cm
	11.5kg
	13KG
_	rigui widii neigit













